Zoetis Inc. (NYSE:ZTS) Stock Holdings Trimmed by Candriam S.C.A.

Candriam S.C.A. lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 498,366 shares of the company's stock after selling 55,974 shares during the period. Candriam S.C.A. owned 0.11% of Zoetis worth $81,199,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Barn Wealth LLC grew its position in shares of Zoetis by 12.9% in the fourth quarter. Blue Barn Wealth LLC now owns 1,801 shares of the company's stock valued at $293,000 after purchasing an additional 206 shares during the period. Freestone Capital Holdings LLC grew its position in shares of Zoetis by 2.7% in the fourth quarter. Freestone Capital Holdings LLC now owns 34,755 shares of the company's stock valued at $5,663,000 after purchasing an additional 906 shares during the period. Ethos Financial Group LLC grew its position in shares of Zoetis by 5.2% in the fourth quarter. Ethos Financial Group LLC now owns 2,053 shares of the company's stock valued at $335,000 after purchasing an additional 101 shares during the period. Lindbrook Capital LLC grew its position in shares of Zoetis by 1.8% in the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock valued at $595,000 after purchasing an additional 65 shares during the period. Finally, Townsend Asset Management Corp NC ADV grew its position in shares of Zoetis by 0.9% in the fourth quarter. Townsend Asset Management Corp NC ADV now owns 23,941 shares of the company's stock valued at $3,901,000 after purchasing an additional 225 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Remove Ads

Zoetis Stock Up 1.8 %

Shares of ZTS traded up $3.09 during midday trading on Friday, reaching $170.34. 3,296,788 shares of the company were exchanged, compared to its average volume of 3,274,650. The stock has a 50-day moving average price of $166.72 and a 200-day moving average price of $176.74. The company has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.